Moreover, the finding that SN-401 robustly increases serum FGF21 levels may provide an additional secondary metabolic molecular mechanism for the observed improvements in glucose metabolism, and hepatic steatosis observed in these SN-401 treated T2D models and warrants future investigation. This evidence concerns the gene FGF21 and fatty liver disease.